Actively Recruiting

Phase Not Applicable
Age: 65Years +
All Genders
NCT07030673

Early Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection

Led by Centre Hospitalier Universitaire, Amiens · Updated on 2026-01-16

256

Participants Needed

1

Research Sites

119 weeks

Total Duration

On this page

Sponsors

C

Centre Hospitalier Universitaire, Amiens

Lead Sponsor

U

University Hospital, Rouen

Collaborating Sponsor

AI-Summary

What this Trial Is About

Among winter respiratory viruses, influenza is the most common and therefore responsible for the highest mortality, but parainfluenza and RSV viruses have an even higher risk of mortality (1.6 to 1.9 times), this toll being paid mainly by the elderly and co-morbid population. Futhermore, SARS-Cov2 will probably become endemic and/or epidemic with the same targets of fragile patients. These viral infections are serious, however a bacterial co-infection worsens the prognosis even more: excess risk of mortality = 2.6, 95% CI \[1.9-3.7\]. Although rare, these co-infections are the subject of a prescription of antibiotics in more than 50% of influenza infections or other serious viral infections. Mainly due to this excess risk of mortality associated with the difficulty of diagnosing these co-infections. Proper antibiotic use requires preventing this misuse and its harmful consequences in the short and long term at all costs. It is therefore imperative to have solid (grade A) evidence showing that antibiotic therapy in viral infections is not only futile but also potentially harmful.

CONDITIONS

Official Title

Early Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection

Who Can Participate

Age: 65Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients ≥ 65 years affiliated to a social security scheme

  • Hospitalized for a lower respiratory infection defined as:

    • the presence of 2 of the following 4 signs:
    • hyperthermia >38°C,
    • hyperleukocytosis ≥12000 or ≤4000,
    • purulent aspirations/sputum,
    • rales on pulmonary auscultation indicating parenchymal damage
    • associated with a pulmonary image (standard X-ray, CT scan or ultrasound)

  • Microbiological diagnostic sample taken within 48 hours

  • Informed consent of the patient or their representative

Not Eligible

You will not qualify if you...

  • Hospitalization planned for < 48 hours or transfer planned to another center within 7 days

    • Patient in septic shock,
    • Febrile aplasia
    • Absence of diagnostic microbiological sampling (> 48 hours after admission)
    • Moribund patient,
    • Death expected within the week
    • Inhalation proven by endoscopy or eyewitness
    • Purulent pleurisy, lung abscess, or other concomitant bacterial infection requiring antibiotic therapy.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

CHRU Amiens

Amiens, France, 80054

Actively Recruiting

Loading map...

Research Team

J

Jean-Philippe LANOIX, Pr

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Early Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection | DecenTrialz